Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...
Researchers engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five ...
Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical for advanced hepatocellular carcinoma. The therapy uses a GPC3-targeting ...
The FDA has granted Breakthrough Device Designation to PreveCol, a blood test for early colorectal cancer detection developed by Amadix. PreveCol excels in identifying precancerous lesions more ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...
Techsomed Medical Technologies announces that the US Food and Drug Administration (FDA) has granted De Novo clearance for its BioTraceIO, an ultrasound-based liver ablation software. This innovative ...
The FDA has approved the Altius® System, an innovative device for managing chronic pain in lower limb amputees. Utilizing direct electrical nerve stimulation, the device proved effective in reducing ...
An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...
Novartis announces its EUR 2.7 billion acquisition of MorphoSys AG, enhancing its oncology pipeline with promising treatments like pelabresib for myelofibrosis and tulmimetostat for solid tumors. The ...
A new PNAS study unveils a hidden vulnerability of prostate cancer: the protein-disulfide isomerases PDIA1 and PDIA5, which stabilize androgen receptor and sustain tumor survival. Inhibition of these ...
Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer treatment—SkinJect, a novel microneedle patch designed to eradicate cancerous cells ...
Everest Medicines' licensing partner Calliditas Therapeutics announced that the FDA approved Nefecon to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback